Table 2. Comparison of changes from baseline within and between oxaloacetate/vitamin C and placebo.
| Characteristics | Oxaloacetate | Placebo | P-valueb) | |||||
|---|---|---|---|---|---|---|---|---|
| Mean improvement (%) | Standard error (%) | P-valuea) | Mean improvement (%) | Standard error (%) | P-valuea) | |||
| Part A | ||||||||
| Becks depression | 52.2 | ±8.8 | <0.0001 | 25.9 | ±13.7 | <0.05 | <0.05 | |
| Cohen perceived stress | 36.2 | ±6.6 | <0.0001 | 21.4 | ±10.2 | <0.05 | <0.05 | |
| Generalized anxiety disorder | 51.3 | ±8.8 | <0.0001 | 24.0 | ±14.0 | <0.05 | <0.05 | |
| Buss-Perry aggression | 15.4 | ±4.8 | 0.0001 | 6.5 | ±5.9 | 0.128 | 0.060 | |
| Part B | ||||||||
| Becks depression | 56.4 | ±5.8 | <0.0001 | 28.1 | ±6.3 | <0.001 | <0.01 | |
| Cohen perceived stress | 37.4 | ±4.7 | <0.0001 | 15.0 | ±4.1 | <0.05 | 0.001 | |
| Generalized anxiety disorder | 52.6 | ±6.4 | <0.0001 | 15.1 | ±12.2 | 0.231 | <0.01 | |
| Buss-Perry aggression | 18.8 | ±4.0 | 0.0001 | 6.2 | ±3.9 | 0.132 | 0.01 | |
a)P-value for evaluating changes from baseline within treatment group; b)P-value for evaluating changes from baseline between oxaloacetate and placebo group (primary analysis).